Levodopa-induced dyskinesias are improved by fluoxetine.
about
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesWorsening of levodopa-induced dyskinesias by motor and mental tasksBupropion-induced acute dystonia.SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.Parkinson's disease: medical treatment of moderate to advanced disease.5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.Monoamine reuptake inhibitors in Parkinson's disease.Present and future drug treatment for Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Nondopaminergic mechanisms in levodopa-induced dyskinesia.Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian ratsTranslation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brainFuture directions in the treatment of Parkinson's disease.Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian ratsThe serotonergic system in motor and non-motor manifestations of Parkinson's disease.Emerging drugs for levodopa-induced dyskinesia.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Quantification of dyskinesia in Parkinson's disease: validation of a novel instrumental method.Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.Movement disturbances associated with the use of selective serotonin-reuptake inhibitors.Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study.MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
P2860
Q24647141-BCE12DE9-C689-45D5-A34A-20F1B6AA15D3Q28066691-A8333AAB-2186-488B-8D59-D837D5021BB2Q28372142-42C75B9E-84F1-4D73-BC14-E8D6112A5474Q30308716-0351EC08-2CC4-41C4-A15B-4600E428DF1AQ34067137-6611683E-404F-421E-827B-CA5348322C55Q34666449-A254A671-B11B-484E-94F7-1F2BF591E2C9Q35015786-4DD78321-ABFE-4CA6-AA3A-9128B48FFE0AQ35165280-69EB0161-3133-417D-B217-05E899ABC2DAQ35484805-AE8A2217-B0D9-4E34-881E-DB52320A7B3FQ35589979-081C1CCB-3A10-4493-8FAC-3A47C70D7C46Q36188913-01B7CD3A-E806-432D-9F4A-15AC43024620Q36243814-16A415DE-88E1-4A90-8C67-7C4D324C32B0Q36549794-867E5598-D93D-4D8D-AFE0-992A04022408Q36851713-498BFACC-E4BA-4BB0-9B81-673CCF4C85E2Q37050653-66A3C8A6-F4B6-48B0-933C-0F9512029C23Q37077360-1F481657-019D-4356-AB34-18FEE8BF2731Q37397245-C7EDF746-802D-474A-9EDC-9BA857465D11Q38118061-2D9AAA03-24B6-4E6E-8D90-6921FC250FBAQ38242091-8A1AF211-9B20-4DA7-9899-4E6DA20D3235Q41645312-F6D31EC9-BC81-4896-AFC7-99AAC10F5F36Q41691617-142B8392-6DE9-48BA-A7A8-8778FFEB9DC4Q42464432-153C6DA9-DD35-4C82-8C18-CF529C093F64Q43693346-936DD644-172B-4FC3-9383-E357A97062B8Q46834396-4D516352-D23C-4678-8C7D-F81CCF8E9F64Q48300577-E8631C1F-8808-4BBE-8352-49ED9008160BQ50880422-CD6ED013-BE81-47B3-BC93-D0286116667DQ51504292-87BB719D-E3F3-4F33-BB7B-4149CA7890CBQ53593907-F83653A7-2CF0-422C-8D3B-805B31C75EBA
P2860
Levodopa-induced dyskinesias are improved by fluoxetine.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Levodopa-induced dyskinesias are improved by fluoxetine.
@en
Levodopa-induced dyskinesias are improved by fluoxetine.
@nl
type
label
Levodopa-induced dyskinesias are improved by fluoxetine.
@en
Levodopa-induced dyskinesias are improved by fluoxetine.
@nl
prefLabel
Levodopa-induced dyskinesias are improved by fluoxetine.
@en
Levodopa-induced dyskinesias are improved by fluoxetine.
@nl
P2093
P356
P1433
P1476
Levodopa-induced dyskinesias are improved by fluoxetine.
@en
P2093
P304
P356
10.1212/WNL.45.10.1855
P407
P50
P577
1995-10-01T00:00:00Z